Neotis offers a senotherapy platform that discovers and develops agents to selectively eliminate or modulate senescent cells, addressing the root cause of age‑related diseases. Using AI‑driven target identification, high‑throughput screening, and pre‑clinical validation, the company creates senolytic and senomorphic candidates along with clinical‑grade biomarker panels for precise dosing and monitoring. Its modular licensing model enables pharmaceutical and biotech partners to co‑develop or acquire these therapies for ageing‑related indications.
Funding
Funding not disclosed
Founders
Product
Problem
Age‑related diseases are driven by the accumulation of senescent cells, yet existing treatments do not specifically target these cells, leading to limited efficacy and side‑effects.
Solution
Neotis builds a senotherapy platform that discovers, validates, and commercializes agents that selectively eliminate or modulate senescent cells. The company combines high‑throughput screening with computational biology to identify novel senolytic and senomorphic targets. Lead candidates are advanced through pre‑clinical models that demonstrate reduction of senescent cell burden and improvement of tissue function. Biomarker panels are developed to monitor senescence clearance in patients, enabling precise dosing and outcome tracking. Neotis partners with pharmaceutical companies to integrate its candidates into broader therapeutic programs for ageing‑related indications.
Target Audience
Primary customers are pharmaceutical and biotech companies developing treatments for ageing‑related diseases, as well as academic research groups focused on cellular senescence.
Features
- Integrated AI‑driven pipeline for senescent‑cell target identification and compound optimization
- Proprietary high‑throughput screening assays that measure senescence markers and cell‑death selectivity
- Pre‑clinical validation suite including mouse models of frailty, osteoarthritis, and metabolic dysfunction
- Clinical‑grade biomarker panels (e.g., SASP proteins, circulating p16^INK4a) for patient stratification and response monitoring
- Modular licensing model allowing pharma partners to co‑develop or acquire full therapeutic programs